Key Drivers
- Strong Liquidity
- No Revenue
- Burn Easing
AIAI Summary
TRVI's investment case has shifted from a financing-survival story to a high-stakes Phase 3 validation story: with cash now extending to 2030, the stock only works if Haduvio delivers reproducible late-stage efficacy, because the current ~$2.1B valuation already prices in meaningful success and leaves little room for disappointment.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •No Revenue
- •Burn Easing
TRVI has a strong cash cushion and very low leverage, but zero revenue, ongoing losses, and reduced but still significant cash burn keep execution risk high and make the current valuation look demanding.
Price Behavior
Key Price Behavior Insights:
- •Support Held
- •Resistance Capped
- •Momentum Fading
TRVI has been range-bound over the last month, with buyers defending $13.76–$13.83 but momentum fading after repeated failures near $15.27–$15.40, so holding $14.00–$13.76 is the key near-term test.
Sharp drop from $15.27 on 2026-05-13 to $14.20 on 2026-05-15 signaled fading momentum
Sentiment & News
Key News Insights:
- •Funding boost
- •Trial progress
- •Data catalyst
Trevi Therapeutics strengthened its balance sheet with two stock offerings, extending cash runway into 2030, while advancing Haduvio's chronic cough program and preparing new trial starts and conference data readouts.
The extended runway and upcoming clinical updates are supportive for the stock, but execution on trial milestones will be the main driver of sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings